AgileBio Tech LTD — Tokenized Dual-Asset Biotech Incubator

The Problem

Biotech doesn't fail for lack of science. It fails for lack of patient capital.

The venture model that funds life sciences was built for software. A SaaS company can be built and exited inside a ten-year fund. A cancer therapy cannot — and the mismatch strands brilliant science between grant money that has run out and commercial capital that arrives too late.

The constraint is the clock

Drug development outlasts the patience of conventional fund structures. The pipeline of ideas isn't the bottleneck — the fund-life clock is.

Dilution arrives at the worst moment

Founders give up ownership precisely when their work starts to matter, on terms set by capital that holds all the leverage.

What if the funding engine had no clock?

A permanent, appreciating treasury — not a depleting fund — pays for the science underneath it.

The Integrated Model

Three engines, one structure

Capital enters once through the STO, funds two engines that feed a shared revenue pool, and returns to token holders three ways — while monetized science recycles back into the treasury to compound the loop.

Diagram: capital flows from the STO into the treasury and incubator engines, aggregates as revenue, and returns to token holders through dividend, buyback-and-burn, and secondary liquidity.

Capital flows from the STO into the treasury and incubator engines, aggregates as revenue, and returns to token holders through dividend, buyback-and-burn, and secondary liquidity.

Open the full-size diagram

The Engine

Digital-asset treasury

90% of the raise is held as a diversified BTC / ETH core with a stablecoin and tokenized-RWA sleeve, in segregated, insured, multi-signature custody. Its appreciation funds everything downstream — non-dilutively.

The Work

Biotech incubator

A curated portfolio where capital is released only against milestones an independent committee has verified, then monetized through licensing, royalties, and exits — diversifying the enterprise away from single-asset volatility.

The Alignment

The ABT token

A perpetual-preferred security token that pays a quarterly dividend, accretes through rules-based buyback-and-burn, and trades on regulated secondary venues for genuine liquidity and price discovery.

Financial Projections

The model, across four scenarios

Calibrated to Bitcoin's actual five-year performance — an average annual return near 52%, a best year of +165% and a worst of −65% — and run from a prolonged crypto winter to a sustained bull market.

All figures are illustrative and scenario-dependent. They are not a forecast, an offer, or a guarantee of any outcome.

Scenario

Digital-asset treasury growth

5-year projection by scenario (US$M)

Source: AgileBio Tech five-year model, calibrated to Bitcoin's 2021–2025 performance (avg. annual return ~52%; best +165%, worst −65%). Treasury seeded at $45M (90% of a $50M STO).

NAV per ABT token

5-year projection, $100 face value

Source: AgileBio Tech model. NAV per token derived from treasury value plus monetized IP and exits, net of fees, divided by tokens outstanding after buyback-and-burn. $100 face value at issue.

Cumulative net income

5-year projection by scenario (US$M)

Source: AgileBio Tech model. Cumulative net income = treasury gains + IP monetization + startup exits, less management fee and operating expense. The Bear path dips negative before recovering.

Investor CAGR

5-year compound annual growth rate

Source: AgileBio Tech model. Five-year CAGR to token holders by scenario, combining NAV accretion and reinvested dividends. Bear preserves capital (~3%) while continuing to pay a dividend.

Sensitivity of Year-5 NAV

±20% on each value driver (Moderate base)

Source: AgileBio Tech model. One-at-a-time ±20% shift on each driver from the Moderate Year-5 base of $1,549. Digital-asset returns dominate; IP revenue and exits are smaller, less volatile contributors.

Risk-return profile

Volatility vs. average annual return

Source: AgileBio Tech model. Annualized volatility (x) vs. average annual return (y) by scenario. The Moderate scenario sits toward the favourable low-volatility, high-return region.

Year-5 revenue & expense waterfall

Moderate scenario (US$M)

Source: AgileBio Tech model, Moderate scenario, Year 5. Builds from treasury gains through IP and exits, less management fee (~$22M) and operating expense (~$7M), to net income of ~$211M.

Use of proceeds

90% managed treasury, 10% operating reserve

Source: AgileBio Tech capital structure. Of the $50M raised, 90% funds the managed treasury (Bitcoin 54%, Ethereum 27%, stablecoins & RWAs 9%) and 10% the operating reserve.

An Honest Word on Risk

Real risks, structurally bounded

The structure is designed to make risk legible and bounded — not to pretend it's small. Each principal risk has a structural answer, not a rhetorical one.

Digital-asset volatility

A treasury weighted to BTC/ETH carries real price risk; the returns that make the upside compelling can compress hard in a downturn.

Mitigation: diversification, rules-based rebalancing, and Bitcoin-backed credit instead of forced sales.

Biotech development risk

Trials fail, timelines slip, and not every IP asset monetizes. Frontier science is intrinsically uncertain.

Mitigation: milestone-gating caps capital-at-risk per company; a portfolio approach replaces the single-drug bet.

Regulatory & liquidity risk

Rules in digital assets and life sciences keep evolving, and early secondary trading may be limited.

Mitigation: a compliant STO with KYC/AML, institutional custody, and listings on regulated venues.

Sequencing at a Glance

From launch to a self-sustaining ecosystem

0–6 MONTHS

Foundation & launch

Close the $50M STO, secure regulatory approvals, deploy the treasury, and stand up independent governance and custody before capital moves.

7–12 MONTHS

Incubator live

Recruit the first cohort of 5–7 startups under a milestone-gating engine, publish daily NAV, and secure a compliant secondary-market listing for the ABT token.

YEAR 2

Growth & first revenue

Execute the first IP monetization deal, expand to 10–15 companies, and activate the rules-based buyback-and-burn program.

YEARS 3–5

Scale & profitability

Achieve the first portfolio exit, scale to 20–25 companies, reach consistent profitability, and explore a second therapeutic area or fund.

Funding the cures of tomorrow with the treasury of today